Sawai Group Holdings Co., Ltd. (TYO:4887)

Revenue by Product

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015
Cardiovascular Drugs	42.57B
Cardiovascular Drugs Growth	1.02%
Central Nervous System Drugs	25.71B
Central Nervous System Drugs Growth	4.64%
Other Metabolic Drugs	20.56B
Other Metabolic Drugs Growth	13.32%
Digestive Medicine	20.40B
Digestive Medicine Growth	6.88%
Blood and Body Fluid Drugs	17.82B
Blood and Body Fluid Drugs Growth	11.32%
Antibiotics	10.67B
Antibiotics Growth	15.09%
Allergy Medications	8.90B
Allergy Medications Growth	28.01%
Vitamin Supplements	7.12B
Vitamin Supplements Growth	-3.37%
Chemotherapeutic Agents	7.02B
Other	28.26B
Other Growth	3.76%

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015
Japan	189.02B
Japan Growth	6.88%